1. Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis 
Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu, Victoria Ward, Lesley S. Exton, M. Firouz Mohd Mustapa, Eleanor Samarasekera, A. David Burden, Ruth Murphy, Caroline M. Owen, Richard Parslew, Vanessa Venning, Richard B. Warren, Catherine H. Smith 
Journal of Investigative Dermatology 
Volume 137, Issue 12, Pages (December 2017)
DOI: /j.jid
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Efficacy compared with tolerability at weeks 12 to 16 based on Figure 1 from Reich et al. Risk differences from Table 1 of Jabbar-Lopez et al. (2017). ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PBO, placebo; SEC, secukinumab; UST, ustekinumab.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2017 The Authors Terms and Conditions